

30 April 2013

ASX ANNOUNCEMENT

APPENDIX 4C - QUARTERLY CASH FLOW

Analytica Limited (the Company) presents its Appendix 4C for the quarter ended 31st March 2013.

Cash Position

The Company held cash reserves at the end of the period of \$322,000.

Research and development expenditure (\$151k), staff costs (\$140k), marketing expenses (\$23k) accounted for the bulk of the operating cash flows for the quarter.

The Company continues to have a line of credit of \$400,000 to ensure adequate funding of the Company.

A receipt of \$498,000 for Research and Development taxation incentive is expected this quarter.

The company does not expect to raise further capital this quarter as material transactions are in progress which are not reflected in the current share price. Analytica's cash equivalents are in excess of \$1.0M which is sufficient for the next two quarters.

Brazil

During the March quarter our Operations Manager travelled to Brazil to demonstrate the AutoStart Burette to CBS Médico Científica (CBS) and to conduct training for CBS representatives. In the previous quarter CBS had signed a letter of intent to distribute the AutoStart burette in Brazil. As well as training, CBS warehousing operations were inspected, and several hospitals visited. Discussions were held with regulatory consultants to progress the product's registration in Brazil. Legal representation was engaged for the preparation and translation of agreements.

Our Brazilian legal representatives have prepared a distribution agreement and the terms and time frames of the agreement are being negotiated. Whilst we initially anticipated a distribution agreement in April, the scope of the agreement has been widened to accommodate the revised business plan

The AutoStart Burette was well received by CBS and as a result they conducted a preliminary sales survey of 14 hospitals, where the product's innovative features were valued. As an outcome of this initial survey, it was determined to conduct a comprehensive study across the hospital sector and health centres to develop the business plan. This will occur in parallel with the pursuit of satisfying regulatory requirements, recognising that even though the product is FDA approved, the process in Brazil will take time. Our market development partners South-South Capital Partners are coordinating both the business plan development and pursuit of the regulatory process.

Other Markets

Late last year a major multinational supplier of medical devices in the United States requested some of our AutoStart Burettes for testing purposes by their engineers. Analytica sent burettes made in our new manufacturing facility in China and after rigorous testing were passed by their engineers. Marketing efforts are continuing with this company and we are hopeful of further developments.

Analysis of the Asia market is progressing well and potential distributors have been identified in particular regions of this market. Meetings are scheduled for the coming month to advance these discussions and an update to the market will be released at an appropriate time.

Products in Development

Progress with the pelvic floor exercise device for the treatment of female incontinence is accelerating. Software and database contracts are currently being finalised. The project is on schedule to release product before Christmas this year.

For, and on behalf of the board,

Dr Michael Monsour

Chairman, Board of Directors

Company announcements are now available via an email mailing list. Visit the company website <http://www.analyticamedical.com> to subscribe.

Analytica Limited (ASX:ALT) is an Australian company dedicated to the design, development and supply of a range of Class I and IIa medical devices.

CBS Medico Cientifica (CBS) is one of the largest participants in the South American medical devices and supplies market. CBS remains a family owned company after four decades of operation. With over 200 employees and contractors CBS has a national footprint and is a multi award winning enterprise for the distribution of 3M medical products. With sales turnover in excess of US\$100m, CBS are projecting 30% YoY growth in 2013, reflecting their market position and the potential for growth in the health sector in Brazil. More information about CBS can be found at their website: www.cbsmed.com.br.



Appendix 4C

Quarterly report for entities admitted on the basis of commitments

Introduced 31/3/2000. Amended 30/9/2001

Name of entity

Analytica Limited

ABN

12 006 464 866

Quarter ended ("current quarter")

31 March 2013

Consolidated statement of cash flows

Cash flows related to operating activities		Current quarter \$A'000	Year to date (9 months) \$A'000
1.1	Receipts from customers		
1.2	Payments for		
	(a) staff costs	(140)	(428)
	(b) advertising and marketing	(23)	(80)
	(c) research and development	(151)	(408)
	(d) leased assets	-	-
	(e) other working capital	6	(182)
1.3	Dividends received	-	-
1.4	Interest and other items of a similar nature received	5	28
1.5	Interest and other costs of finance paid	-	-
1.6	Income taxes paid	-	-
1.7	Other-		
	(a) Net sales income	-	-
	(b) R & D Tax Concession	-	158
	(c) Royalty Income	3	10
Net operating cash flows		(299)	(902)

+ See chapter 19 for defined terms.

Appendix 4C
Quarterly report for entities
admitted on the basis of commitments

	Current quarter \$A'000	Year to date (9 months) \$A'000
1.8 Net operating cash flows (carried forward)	(299)	(902)
Cash flows related to investing activities		
1.9 Payment for acquisition of:		
(a) businesses	-	-
(b) equity investments	-	-
(c) intellectual property	-	-
(d) physical non-current assets	-	(5)
(e) other non-current assets	-	-
1.10 Proceeds from disposal of:		
(a) businesses	-	-
(b) equity investments	-	-
(c) intellectual property	-	-
(d) physical non-current assets	-	-
(e) other non-current assets	-	-
1.11 Loans to other entities	-	-
1.12 Loans repaid by other entities	-	-
1.13 Other (purchase of Convertible Notes)	-	-
Net investing cash flows	-	(5)
1.14 Total operating and investing cash flows	(299)	(907)
Cash flows related to financing activities		
1.15 Proceeds from issues of shares	-	4
1.16 Proceeds from sale of forfeited shares	-	-
1.17 Proceeds from borrowings	12	12
1.18 Repayment of borrowings:	-	-
1.19 Dividends paid	-	-
1.20 Other Creditors (costs of fund raising)	-	-
Net financing cash flows	12	16
Net increase (decrease) in cash held	(287)	(891)
1.21 Cash at beginning of quarter/year to date	609	1213
1.22 Exchange rate adjustments to item 1.20	-	-
1.23 Cash at end of quarter	322	322

+ See chapter 19 for defined terms.

Payments to directors of the entity and associates of the directors

Payments to related entities of the entity and associates of the related entities

		Current quarter \$A'000
1.24	Aggregate amount of payments to the parties included in item 1.2	48
1.25	Aggregate amount of loans to the parties included in item 1.11	13
1.26	Explanation necessary for an understanding of the transactions	
	Payment of director's fees and compulsory superannuation.	

Non-cash financing and investing activities

- 2.1 Details of financing and investing transactions which have had a material effect on consolidated assets and liabilities but did not involve cash flows

N/A

- 2.2 Details of outlays made by other entities to establish or increase their share in businesses in which the reporting entity has an interest

N/A

Financing facilities available

Add notes as necessary for an understanding of the position. (See AASB 1026 paragraph 12.2).

	Amount available \$A'000	Amount used \$A'000
3.1 Loan facilities	400	-
3.2 Credit standby arrangements	-	-

+ See chapter 19 for defined terms.

Reconciliation of cash

Reconciliation of cash at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts is as follows.		Current quarter \$A'000	Previous quarter \$A'000
4.1	Cash on hand and at bank	322	609
4.2	Deposits at call	-	-
4.3	Bank overdraft	-	-
4.4	Other (provide details)	-	-
Total: cash at end of quarter (item 1.23)		322	609

Acquisitions and disposals of business entities

	Acquisitions	Disposals
5.1	Name of entity	N/A
5.2	Place of incorporation or registration	
5.3	Consideration for acquisition or disposal	
5.4	Total net assets	
5.5	Nature of business	

Compliance statement

- 1 This statement has been prepared under accounting policies which comply with accounting standards as defined in the Corporations Act (except to the extent that information is not required because of note 2) or other standards acceptable to ASX.
- 2 This statement does give a true and fair view of the matters disclosed.

Sign here: ORIGINAL SIGNED

Date: 30/4/2013

Print name: Ross Mangelsdorf

+ See chapter 19 for defined terms.